Article
Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
The pharmacogenomics journal - 1 Oct 2012
Salazar J, Altés A, del Río E, Estella J, Rives S, Tasso M, Navajas A, Molina J, Villa M, Vivanco J L, Torrent M, Baiget M, Badell I
Abstract excerpt
Recent advances in treatment for childhood acute lymphoblastic leukaemia (ALL) have significantly increased outcome. High-dose methotrexate (MTX) is the most commonly used regimen during the consolidation period, but the optimal dose remains to be defined. We investigated the usefulness of the MTHFR genotype to increase the MTX dosage in the consolidation phase in 141 childhood ALL patients enrolled in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.